Beijing launches 32 measures to promote innovative and high-quality development of the pharmaceutical industry.

Yesterday, the "Several Measures to Support the High-Quality Development of Innovative Pharmaceutical Industry in Beijing" were officially launched, aiming to further accelerate the innovation of Beijing's pharmaceutical and health industry, continuously build a full chain support system of "Research and Development-Approval-Production-Application," provide precise, stable, and predictable policy environment for innovative pharmaceutical companies, and comprehensively stimulate the development of new quality productive forces. The 32 new measures released in this announcement will adhere to the leading role of Beijing as an international science and technology innovation center, closely follow the forefront of medical technology development, and layout original innovation. In particular, for drug technology evaluation and market approval, the Beijing Drug Administration will intervene early, providing consultation services and technical guidance. For drugs produced overseas and marketed domestically, if significant changes occur in formulation, production processes, production sites, quality standards, etc., the drug regulatory department will optimize the review process and improve the efficiency and effectiveness of evaluation and approval without reducing procedures or standards.